2026年9月29日，亚盛医药（06855）公告披露，受托人已于2026年9月28日通过场内交易购入公司现有股份5万股，用于履行2022年受限制股份单位计划的归属安排。
公告要点如下： 1. 购股数量：50,000股，占截至公告日期已发行股份总数的约0.01%。 2. 总代价：1,428,000港元（不含相关费用及税项）。 3. 平均购股价格：约28.56港元/股（不含相关费用及税项）。 4. 截至此次交易完成后，受托人已累计为2022年受限制股份单位计划于场内购入股份2,715,000股。
公司强调，受托人持股将依据信托契据及计划规则进行管理，受托人不得行使相关表决权。截至公告日，除已披露的各次首次及进步授出外，公司未有新增奖励授出计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.